"Ipilimumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.
| Descriptor ID |
D000074324
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.798 D12.776.124.790.651.114.224.060.798 D12.776.377.715.548.114.224.200.798
|
| Concept/Terms |
Ipilimumab- Ipilimumab
- Anti-CTLA-4 MAb Ipilimumab
- Anti CTLA 4 MAb Ipilimumab
- Ipilimumab, Anti-CTLA-4 MAb
|
Below are MeSH descriptors whose meaning is more general than "Ipilimumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Ipilimumab [D12.776.124.486.485.114.224.060.798]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Ipilimumab [D12.776.124.790.651.114.224.060.798]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Ipilimumab [D12.776.377.715.548.114.224.200.798]
Below are MeSH descriptors whose meaning is more specific than "Ipilimumab".
This graph shows the total number of publications written about "Ipilimumab" by people in this website by year, and whether "Ipilimumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 7 | 14 | 21 |
| 2018 | 11 | 7 | 18 |
| 2019 | 8 | 7 | 15 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Ipilimumab" by people in Profiles.
-
Severe cutaneous adverse reaction following COVID-19 vaccination and immunotherapy: a second hit? Clin Exp Dermatol. 2022 01; 47(1):149-151.
-
Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies. Sci Rep. 2021 05 13; 11(1):10220.
-
Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint Inhibition. Front Immunol. 2021; 12:627186.
-
Immune-related pneumonitis with nivolumab and ipilimumab during the coronavirus disease 2019 (COVID-19) pandemic. Eur J Cancer. 2020 08; 135:147-149.
-
COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer. Eur Urol Focus. 2020 Sep 15; 6(5):1086-1096.
-
Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy. J Immunother Cancer. 2020 05; 8(1).
-
Severe Acute Kidney Injury Due to Nivolumab/Ipilimumab-induced Granulomatosis and Fibrinoid Vascular Necrosis. J Immunother. 2020 01; 43(1):29-31.
-
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer. 2019 11; 121:144-153.
-
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019 11 21; 381(21):2020-2031.
-
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019 10 17; 381(16):1535-1546.